ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2181 entries already.
Entries by Thomas Gabrielczyk
Novo Holdings co-leads €40m Qure.ai financing
Deep learning medical imaging specialist Qure.ai raises $40m from healthcare investors Novo Holdings and HealthQuad
Sanofi and IGM Biosciences Inc. in $6.15bn deal
Sanofi and IGM Biosciences have entered into a broad antibody discovery collaboration that could bring in IGM $6bn if all milestones are met.
XNK Therapeutics AB raises €12.75m
XNK Therapeutics AB has secured a private placement of €12.75m led by Flerie Invest AB to finance Phase II development of CellProtect + Isatuximab in multiple myeloma.
Mastering the data revolution of clinical trials
Data Management has been a hotbed for development and innovation, correlating primarily with
the changing digital landscape. Clinical trial management has been significantly impacted, with the
electronic data capture and GDPR-compliance-led industry now unrecognisable from the paper-document administration methods of the past. This development process extends beyond COVID-19 and has a
noticeable impact on clinical trials.
How to Safely Handle Your Antibody Drug Conjugate
ADCs have huge potential in treating challenging diseases such as cancer. However, it is essential that all necessary equipment, steps, and precautions are in place to en¬sure their safe handling.
CSL Behring files for MAA of haemophilia B gene therapy
CSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe.
Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services
Sino Biological, a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.
Argenx SE to raise €637m
Dutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.
Recombinant production
Sino Biological specializes in recombinant production of antibodies and proteins. The company routinely conducts high-throughput projects of up to 1,000 per batch. Sino Biological’s manufacturing facility can also handle large-scale production at gram level.